Switching from TDF to TAF in HIV/HBV co-infected individuals with renal dysfunction - a prospective cohort study.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of acquired immune deficiency syndromes"
DOI: 10.1097/qai.0000000000002429
Abstract: BACKGROUND Whereas tenofovir disoproxil fumarate (TDF) can lead to renal adverse events, tenofovir alafenamide (TAF) has a more favorable renal safety profile. However, the impact of replacing TDF with TAF on renal function and liver… read more here.
Keywords: individuals renal; hiv hbv; egfr min; min 73m ... See more keywords